Key result
Interferon-free anti-HCV therapy is linked to a rapid and sustained increase in platelet counts.
Why the study?
Platelet counts increase after HCV eradication, but the mechanism involving hypersplenism, decreased thrombopoietin, and HCV-induced myelosuppression is not fully understood.
Does interferon-free anti-HCV therapy improve platelet counts in patients with chronic hepatitis C virus infection?
Observational
Does interferon-free anti-HCV therapy improve platelet counts in patients with chronic hepatitis C virus infection?
p-value: p=<0.001
Interferon-free anti-HCV therapy rapidly improves platelet counts, likely due to the improvement of hypersplenism and HCV-induced myelosuppression.
Rapid platelet rise after DAA therapy in thrombocytopenic HCV may reflect reduced hypersplenism and myelosuppression; leaves open prospective confirmation before practice change.
No takes yet. Share an insight, caveat, or question.
Ishizu et al. (2019) conducted an observational in Chronic hepatitis C virus (HCV) infection. Interferon-free anti-HCV therapy vs. Baseline (pre-treatment) was evaluated on Changes in platelet counts (p=<0.001). Interferon-free anti-HCV therapy was associated with a rapid increase in platelet counts at 4 weeks that remained at a plateau until 48 weeks (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: